The antiserum was produced against synthesized peptide derived from human AS160 around the phosphorylation site of Thr642. AA range:611-660

Phospho-TBC1D4 (T642) Polyclonal Antibody detects endogenous levels of TBC1D4 protein only when phosphorylated at T642.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):AHtFS

TBC1D4 AS160 KIAA0603

TBC1 domain family member 4

TBC1D4 ;
AS160 ;
KIAA0603 ;
TBC1 domain family member 4 ;
Akt substrate of 160 kDa ;
AS160

This gene is a member of the Tre-2/BUB2/CDC16 domain family. The protein encoded by this gene is a Rab-GTPase-activating protein, and contains two phopshotyrosine-binding domains (PTB1 and PTB2), a calmodulin-binding domain (CBD), a Rab-GTPase domain, and multiple AKT phosphomotifs. This protein is thought to play an important role in glucose homeostasis by regulating the insulin-dependent trafficking of the glucose transporter 4 (GLUT4), important for removing glucose from the bloodstream into skeletal muscle and fat tissues. Reduced expression of this gene results in an increase in GLUT4 levels at the plasma membrane, suggesting that this protein is important in intracellular retention of GLUT4 under basal conditions. When exposed to insulin, this protein is phosphorylated, dissociates from GLUT4 vesicles, resulting in increased GLUT4 at the cell surface, and enhanced glucose transport. Ph

Disease:May be involved in atopic dermatitis (AD).,Function:May act as a GTPase-activating protein for RAB2A, RAB8A, RAB10 and RAB14. Isoform 2 promotes insulin-induced glucose transporter SLC2A4/GLUT4 translocation at the plasma membrane, thus increasing glucose uptake.,PTM:Insulin-stimulated phosphorylation is required for SLC2A4/GLUT4 translocation.,PTM:Phosphorylated by AKT1; insulin-induced.,PTM:Physiological hyperinsulinemia increases phosphorylation in skeletal muscle. Insulin-stimulated phosphorylation is reduced by 39% in type 2 diabetic patients.,similarity:Contains 1 Rab-GAP TBC domain.,similarity:Contains 2 PID domains.,subcellular location:Isoform 2 shows a cytoplasmic perinuclear localization in a myoblastic cell line in resting and insulin-stimulated cells.,tissue specificity:Widely expressed, but differential expression for isoforms 1 and 2, with highest overall expression of isoform 2 in most tissues. Isoform 1 is highly expressed in skeletal muscle and heart, but was not detectable in the liver nor in adipose tissue. Isoform 2 strongly expressed in adrenal and thyroid gland, and also in lung, kidney, colon, brain and adipose tissue. Moderate isoform 2 expression in skeletal muscle. Expressed in pancreatic Langerhans islets, including beta cells (at protein level). Expression is decreased by twofold in pancreatic islets in type 2 diabetes patients compared to control subjects.,

Cytoplasm . Isoform 2 shows a cytoplasmic perinuclear localization in a myoblastic cell line in resting and insulin-stimulated cells.

Widely expressed. Isoform 2 is the highest overexpressed in most tissues. Isoform 1 is highly expressed in skeletal muscle and heart, but was not detectable in the liver nor in adipose tissue. Isoform 2 is strongly expressed in adrenal and thyroid gland, and also in lung, kidney, colon, brain and adipose tissue. Isoform 2 is moderately expressed in skeletal muscle. Expressed in pancreatic Langerhans islets, including beta cells (at protein level). Expression is decreased by twofold in pancreatic islets in type 2 diabetes patients compared to control subjects. Up-regulated in T-cells from patients with atopic dermatitis.

>>Thyroid hormone signaling pathway ;
>>Insulin resistance ;
>>Diabetic cardiomyopathy